| Bevacizumab | |
| Generic Name | Bevacizumab |
| Trade Name | Avastin |
| Company Name | Roche |
| Drug Type | Antibody |
| Drug Class | Angiogenesis ‐ VEGF |
| Dose | 7.5 milligrams (mg) per kilogram (kg) |
| Route | IV |
| Schedule of Administration | Patients received bevacizumab 7.5 mg/kg on day 1 every 3 weeks |
| S‐1 | |
| Generic Name | S‐1 |
| Trade Name | Tegafur, gimeracil, and oteracil potassium capsules |
| Company Name | Shandong New Time Pharmaceutical Co., Ltd. |
| Drug Type | Small molecule |
| Drug Class | Antimetabolite |
| Dose | BSA <1.25 m2, 80 mg/day; BSA ≥1.25 m2 but <1.5 m2, 100 mg/day; and BSA ≥1.5 m2, 120 mg/day; milligrams (mg) per flat dose milligrams (mg) per squared meter (m2) |
| Route | Oral (p.o.) |
| Schedule of Administration | Patients received S‐1 on days 1–14 every 3 weeks. Dose was based on BSA. |
| Raltitrexed | |
| Generic Name | Raltitrexed |
| Trade Name | Raltitrexed |
| Company Name | Nanjing CHIA TAI Tianqing Pharmaceutical Co. Ltd. |
| Drug Type | Small molecule |
| Drug Class | Antimetabolite |
| Dose | 3 milligrams (mg) per squared meter (m2) |
| Route | IV |
| Schedule of Administration | Patients received raltitrexed 3 mg/m2 on day 1 every 3 weeks |